Biostage (BSTG) Stock Price, News & Analysis

Company Overview

Biostage, Inc. (OTCMKTS: BSTG) is a development‐stage regenerative medicine company dedicated to creating implantable, tissue‐engineered medical devices designed to treat severe organ disorders. The company’s proprietary platform integrates bioscaffolds with a patient’s own cells to produce living implants that can restore structure and function in damaged tissues. Biostage’s mission focuses on addressing unmet medical needs in life‐threatening conditions where conventional therapies offer limited efficacy.

The company’s lead product candidate, the Neo‐Esophagus, is designed to replace or repair sections of the esophagus damaged by congenital defects, cancer resections, or severe trauma. Biostage also has earlier‐stage programs targeting airway reconstruction, leveraging the same scaffold‐and‐autologous‐cell technology. By using a patient’s own cells, the company aims to reduce the risk of rejection and eliminate the need for long‐term immunosuppression. Biostage has secured regulatory clearance to initiate clinical studies for its esophageal repair device and continues to advance its pipeline through preclinical development.

Founded in 2003 under the name Tengion, the company rebranded as Biostage in 2018 to reflect its focus on true tissue regeneration and organ reconstruction. Headquartered in Cambridge, Massachusetts, Biostage operates within the United States, collaborating with research institutions and clinical investigators to drive its development programs forward. The company is led by a management team with extensive experience in biotechnology, medical devices, and regenerative medicine, positioning Biostage to translate its novel platform into potential therapies for patients with critical organ needs.

Key Stats

• Today's Range: $4.45 to $4.45
• 50-Day Range: $4.45 to $4.45
• 52-Week Range: $4.45 to $4.45
• Volume: N/A
• Average Volume: 1,847 shs
• Market Capitalization: $61.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Biostage Stock Analysis - MarketRank™

Biostage scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Biostage has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Biostage has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Biostage is -7.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biostage is -7.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BSTG.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biostage does not currently pay a dividend.

Dividend Growth

Biostage does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for BSTG on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biostage insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.30% of the stock of Biostage is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Biostage has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2020
• Today: 8/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: OTCMKTS:BSTG
• CIK: 1563665
• Web: www.biostage.com
• Phone: (744) 233-7300
• Fax: 774-233-7302
• Employees: 7
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -174.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.73
• Quick Ratio: 2.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.26) per share
• Price / Book: -17.12

Miscellaneous

• Outstanding Shares: 13,882,000
• Free Float: 11,758,000
• Market Cap: $61.77 million
• Optionable: Not Optionable
• Beta: -1.02